IN BRIEF This article reviews the history of phlorizin, the role of the kidney in glucose regulation, and the modulation of that regulatory system via pharmacological means. It also offers a discussion of the results of clinical trials of the most salient sodium glucose co-transporter inhibitor to date: dapagliflozin.
No takes yet. Share an insight, caveat, or question.
John R. White (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: